Walleye Capital
CRSP icon

Walleye Capital’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Sell
18,400
-23,300
-56% -$1.23M ﹤0.01% 2124
2026
Q1 		$1.98M Buy
41,700
+22,300
+115% +$1.18M 0.01% 1469
2025
Q4 		$1.02M Buy
19,400
+10,100
+109% +$605K ﹤0.01% 2414
2025
Q3 		$603K Sell
9,300
-23,500
-72% -$1.35M ﹤0.01% 2472
2025
Q2 		$1.6M Buy
32,800
+14,700
+81% +$569K 0.01% 1688
2025
Q1 		$616K Sell
18,100
-19,900
-52% -$844K ﹤0.01% 2382
2024
Q4 		$1.5M Buy
38,000
+30,000
+375% +$1.42M ﹤0.01% 2044
2024
Q3 		$376K Sell
8,000
-37,200
-82% -$1.89M ﹤0.01% 3555
2024
Q2 		$2.44M Sell
45,200
-3,200
-7% -$185K ﹤0.01% 1919
2024
Q1 		$3.3M Buy
48,400
+24,600
+103% +$1.76M 0.01% 1618
2023
Q4 		$1.49M Buy
23,800
+3,400
+17% +$188K ﹤0.01% 2017
2023
Q3 		$926K Sell
20,400
-2,400
-11% -$124K ﹤0.01% 2307
2023
Q2 		$1.28M Hold
22,800
– – ﹤0.01% 1641
2023
Q1 		$1.03M Sell
22,800
-6,700
-23% -$325K 0.02% 1148
2022
Q4 		$1.2M Buy
29,500
+10,400
+54% +$552K 0.02% 887
2022
Q3 		$1.25M Buy
+19,100
New +$1.38M 0.02% 821
2019
Q4 		– Sell
-9,600
Closed -$394K – 1873
2019
Q3 		$394K Buy
9,600
+2,300
+32% +$110K 0.02% 862
2019
Q2 		$344K Sell
7,300
-500
-6% -$20K 0.04% 667
2019
Q1 		$279K Buy
+7,800
New +$270K 0.05% 632

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's CRSP Position: Q2 2026 in Review

Walleye Capital increased its CRISPR Therapeutics (CRSP) stake by 2,538% in Q2 2026, buying an estimated $1.22M and bringing the position to 24,136 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1886.

Walleye Capital first reported a position in CRSP in Q3 2019 and has held it in 10 quarters since. The position peaked at $5.39M in Q1 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Walleye Capital held 24,136 shares of CRISPR Therapeutics worth $1.32M as of Q2 2026.
  • Walleye Capital bought 23,221 CRISPR Therapeutics shares in Q2 2026, an estimated $1.22M.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #1886 holding.
  • Walleye Capital first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 10 quarters since.
  • Walleye Capital's CRISPR Therapeutics position peaked at $5.39M in Q1 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.